Table 3 summarizes the PD-L1 based approvals that exist in lung, head and neck, bladder, gastric, esophageal, cervical and breast cancer together with the various measures of PD-L1 expression, companion diagnostics and positive thresholds. In summary, PD-L1 remains a highly imperfect biomarker, and other markers of immune responsiveness are simultaneously being tested for (e.g., MSI status, TMB-h) and studied (tumor-infiltrating lymphocytes, tumor microenvironment, etc.)to enable proper selection of treatment with ICIs [174]. This evidence concerns the gene CD274 and breast cancer.